Buprenorphine

Indiana’s First Single Campus, Full Continuum of Addiction Treatment Services is Complete

Retrieved on: 
Monday, February 13, 2023
FDA, White House, Federal Government, Other Professional Services, State, Local, Law Enforcement, Emergency Services, Pharmaceutical, General Health, Professional Services, Women, Seniors, Public Policy, Government, Men, LGBTQ+, Family, Consumer, Health, MAT, Heroin, Methadone, Buprenorphine, Safety, Patient, Anger, Pregnancy, Grief, Food, Research, Parent, Opioid, Trauma, Regulation of tobacco by the U.S. Food and Drug Administration, Service, Naloxone, Pharmaceutical industry, Hospital, Nursing

Martinsville Treatment Services provides medication-assisted treatment (MAT) on an outpatient basis to adults who have become addicted to heroin, prescription painkillers, and other opioids.

Key Points: 
  • Martinsville Treatment Services provides medication-assisted treatment (MAT) on an outpatient basis to adults who have become addicted to heroin, prescription painkillers, and other opioids.
  • “It is no secret that opioid addiction has had a devastating impact in communities throughout Indiana,” said Martinsville Treatment Services Executive Director Kenisha Peden.
  • At Martinsville Treatment Services, patients can receive a prescription for either methadone or Suboxone (which is a combination of buprenorphine and naloxone).
  • For additional information about Martinsville Treatment Services or to schedule a free confidential assessment, call 765-516-6292.

Global Naloxone Market Report 2022 to 2030: Parenteral Segment Dominated the Formulation Market - ResearchAndMarkets.com

Retrieved on: 
Monday, January 30, 2023
Health, Pharmaceutical, Heroin, Drug, Drug overdose, Opioid overdose, Oxycodone, Buprenorphine, Fentanyl, Incidence, Morphine, Death, Growth, Opioid, Injection, Prevalence, Hydrocodone, Hospital, Speciality chemicals, Marketing, Renewable energy, Naloxone, Buprenorphine/naloxone

The global naloxone market is expected to grow at a CAGR of 10.1% during the forecast period of 2022-2030.

Key Points: 
  • The global naloxone market is expected to grow at a CAGR of 10.1% during the forecast period of 2022-2030.
  • The increasing prevalence of opioid overdoses is expected to drive the growth of the naloxone market.
  • An increasing incidence of opioid drug abuse in both the developed and developing worlds remains the key driver for the market growth of the naloxone market.
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Naloxone market worldwide?

Pear Therapeutics and BrightView Health Expand Pilot Program to Provide Prescription Digital Therapeutics for the Treatment of Substance Use Disorders

Retrieved on: 
Thursday, January 26, 2023
Mental Health, Health, Technology, Software, General Health, Pharmaceutical, Biotechnology, MBA, Substance use disorder, PDT, Cognitive behavioral therapy, Policy by press release, OUD, Suicidal ideation, Buprenorphine, Opioid use disorder, Publication, Smartphone, Patient, Brightview, Reset, ABEM, Therapy, Risk, Reading, SUD, Languages of Ethiopia, Multimedia, MD, Pharmaceutical industry, Nursing, Birth control, Hospital, Mobile phone, Medical device, Pear

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today the expansion of its collaboration with BrightView Health , an addiction treatment provider that offers evidence-based, outpatient addiction treatment programs.

Key Points: 
  • Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today the expansion of its collaboration with BrightView Health , an addiction treatment provider that offers evidence-based, outpatient addiction treatment programs.
  • This initiative is designed to provide eligible adults suffering from substance use disorder (SUD) and opioid use disorder (OUD) access to reSET® and reSET-O®.
  • “We believe reSET and reSET-O are beneficial to our patients, the community, and our health system.
  • Increase abstinence from a patient’s substances of abuse during treatment, and
    Increase retention in the outpatient treatment program.

Landmark Recovery's Chief Medical Officer Elected President of Tennessee Society of Addiction Medicine

Retrieved on: 
Wednesday, February 15, 2023
Buprenorphine, Thompson, Addiction medicine, Bed, American Society of Addiction Medicine, Social, Society, ER, Physician, Patient, Pharmaceutical industry

FRANKLIN, Tenn., Feb. 15, 2023 /PRNewswire/ -- Dr. Jason Kirby, chief medical officer at Landmark Recovery, a national addiction treatment provider, was recently elected president of the Tennessee Society of Addiction Medicine (TNSAM).

Key Points: 
  • FRANKLIN, Tenn., Feb. 15, 2023 /PRNewswire/ -- Dr. Jason Kirby, chief medical officer at Landmark Recovery, a national addiction treatment provider, was recently elected president of the Tennessee Society of Addiction Medicine (TNSAM).
  • A chapter of the American Society of Addiction Medicine, TNSAM is comprised of physicians and healthcare providers working to improve the treatment of people experiencing substance use disorder.
  • He also wants to work with Tennessee's academic institutions to recruit more healthcare workers into the addiction treatment industry.
  • He'd like to see rural hospitals utilize addiction consultation services to help get more Tennessee residents into treatment.

Orexo Interim Report Q4 2022, incl. Full Year Report

Retrieved on: 
Thursday, January 26, 2023
USD, Buprenorphine, Orexo, CET, Legislation, FX, CFO, Opioid use disorder, Partnership, OUD, EBIT, ID, Pharmaceutical industry

As expected, EBIT in Q4 was affected by high non-recurring operating costs and the continued strength of the USD.

Key Points: 
  • As expected, EBIT in Q4 was affected by high non-recurring operating costs and the continued strength of the USD.
  • At 2 pm CET the same day as the announcement of the report Orexo invites analysts, investors and media to attend a presentation where Nikolaj Sørensen, CEO and Fredrik Järrsten, CFO, will present the report and host a Q&A.
  • The following files are available for download:
    Orexo Interim Report Q4 2022, incl.
  • Full Year Report

Orexo Interim Report Q4 2022, incl. Full Year Report

Retrieved on: 
Thursday, January 26, 2023
USD, Buprenorphine, Orexo, CET, Legislation, FX, CFO, Opioid use disorder, Partnership, OUD, EBIT, ID, Pharmaceutical industry

As expected, EBIT in Q4 was affected by high non-recurring operating costs and the continued strength of the USD.

Key Points: 
  • As expected, EBIT in Q4 was affected by high non-recurring operating costs and the continued strength of the USD.
  • At 2 pm CET the same day as the announcement of the report Orexo invites analysts, investors and media to attend a presentation where Nikolaj Sørensen, CEO and Fredrik Järrsten, CFO, will present the report and host a Q&A.
  • The following files are available for download:
    Orexo Interim Report Q4 2022, incl.
  • Full Year Report

Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List

Retrieved on: 
Wednesday, January 18, 2023
Software, Pharmaceutical, Managed Care, General Health, Health, Health Technology, Technology, Clinical Trials, Reading, Policy by press release, Publication, PDT, Therapy, Medicaid, Pear, Buprenorphine, Language isolate, United States drug overdose death rates and totals over time, Florida Medicaid waiver, OUD, Methamphetamine, SUD, FDA, Risk, Smartphone, Substance use disorder, Patient, Cannabis, PDL, Cocaine, Suicidal ideation, Reset, CDC, Cognitive behavioral therapy, Opioid use disorder, Pharmaceutical industry, Medical device, Birth control, Hospital, Mobile phone

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the inclusion of its PDTs reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List (PDL).

Key Points: 
  • Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the inclusion of its PDTs reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List (PDL).
  • reSET and reSET-O, the only FDA-authorized PDTs for the treatment of substance use disorder and opioid use disorder, respectively, have been added to the Florida Medicaid PDL, effective January 1, 2023.
  • Increase abstinence from a patient’s substances of abuse during treatment, and
    Increase retention in the outpatient treatment program.
  • The long-term benefit of reSET-O has not been evaluated in studies lasting beyond 12 weeks (84 days) in the OUD population.

FDA Grants Priority Review for Nalmefene Prefilled Syringe for the Treatment of Known or Suspected Opioid Overdose

Retrieved on: 
Wednesday, January 18, 2023
Mental Health, Medical Supplies, Medical Devices, FDA, Health, Pharmaceutical, Practitioner, Purdue University, Hypertension, Pulmonary edema, Oxygen, Buprenorphine, Nalmefene, Purdue Pharma, Safety, Abbreviated New Drug Application, Nursing, MD, HCI, Risk, Hypotension, Ventricular fibrillation, LAAM, ANDA, Methadone, Patient, Prevalence, Mortality, Tachycardia, Recurrence, Ventricular tachycardia, Hypersensitivity, Fentanyl, Hypoventilation, Naloxone, Physician, Pharmaceutical industry, Cereal, Generic drug

* Nalmefene is an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids, and in the management of known or suspected opioid overdose.

Key Points: 
  • * Nalmefene is an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids, and in the management of known or suspected opioid overdose.
  • In addition, FDA previously granted Competitive Generic Therapy designation for the prefilled syringe and the nalmefene hydrochloride injection vial.
  • There is no guarantee that nalmefene prefilled syringe will successfully complete development or gain FDA approval.
  • Nalmefene Hydrochloride Injection is indicated in the management of known or suspected opioid overdose.

Pear Therapeutics and COEUS Healthcare Partner to Combat the Addiction Crisis With Prescription Digital Therapeutics

Retrieved on: 
Tuesday, January 10, 2023
Health, Technology, Health Technology, Managed Care, Software, General Health, Pharmaceutical, PDT, Reading, Press release, Therapy, Medicaid, Pear, Buprenorphine, Language isolate, OUD, CMS, Government, Centers for Medicare & Medicaid Services, SUD, Risk, Smartphone, Substance use disorder, Medicare, Patient, Suicidal ideation, Reset, Multimedia, Commercial, Cognitive behavioral therapy, Opioid use disorder, Pharmaceutical industry, Health insurance, Birth control, Hospital, Mobile phone, Medical device

Pear Therapeutics, Inc. (Nasdaq: PEAR) (“Pear”), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced an agreement with COEUS HealthCare, LLC (“COEUS”), a leading life sciences technology and consulting firm, to utilize its outcomes and evidence-based reimbursement adjudication platform, COEBRA™ to help enable value-based contracting.

Key Points: 
  • Pear Therapeutics, Inc. (Nasdaq: PEAR) (“Pear”), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced an agreement with COEUS HealthCare, LLC (“COEUS”), a leading life sciences technology and consulting firm, to utilize its outcomes and evidence-based reimbursement adjudication platform, COEBRA™ to help enable value-based contracting.
  • The agreement between COEUS and Pear could help unlock the potential value that Pear’s PDTs can deliver.
  • Hosting PDTs on the COEUS COEBRATM Platform is intended to provide scalability for Pear across multiple channels including Medicaid, Commercial and other government payers.
  • As part of the agreement, COEUS will provide Pear a turnkey value-based solution that will be made available to most state Medicaid programs.

MAT Act Signed Into Law, NABP Applauds Benefits for Overdose Prevention and Recovery Support

Retrieved on: 
Thursday, January 5, 2023
Doctor of Pharmacy, Legislation, Friends, National Association, Office of National Drug Control Policy, Public health, MS, House, Democrat, Republican, Senate, Buprenorphine, Organization, White House, Omnibus spending bill, Pharmacist, Opioid use disorder, NABP, MAT, Policy, White, OUD, Hospital, Drug, Pharmacy, Congress, Consolidated Appropriations Act, 2021, SUD, Pharmaceutical industry

The MAT Act will help turn the tide of the overdose crisis by saving thousands of lives from overdoses and supporting long-term recovery from OUD.

Key Points: 
  • The MAT Act will help turn the tide of the overdose crisis by saving thousands of lives from overdoses and supporting long-term recovery from OUD.
  • By passing the MAT Act, Congress has acted to prevent future overdose deaths and support people with SUD in securing recovery.
  • NABP is one of nearly 550 organizations that called on Congress and the White House to pass the MAT Act.
  • The MAT Act was among the most broadly supported pieces of overdose prevention legislation introduced this session.